PR Newswire BiotechOriginal article
Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
Phase 2AK138D1ivonescimabPositive
AI Analysis
Summary
Akeso announces first patient dosed in Phase Ib/II study (AK138D1-201) evaluating next-generation HER3 ADC AK138D1 combined with ivonescimab for lung cancer treatment as part of its Akeso IO2.0 + ADC2.0 strategy advancement.
Clinical Trial Data
Phase
Ib/II
Patients
1
Outcome Details
first patient dosed in Phase Ib/II study
Importance:6/10
Sentiment:
0.60
HER3 ADCADC2.0 strategyIO2.0 strategycombination therapyoncologylung cancer
Read the original article
Published by PR Newswire Biotech on July 28, 2026 2:35 AM